Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a leading biotechnology company headquartered in the United States, focuses on innovative aesthetic and therapeutic solutions. Founded in 2011, Revance has made significant strides in the industry, particularly with its proprietary DaxibotulinumtoxinA injection, which offers a unique, long-lasting alternative to traditional neuromodulators. With a strong presence in the aesthetic and therapeutic sectors, Revance is committed to advancing patient care through its cutting-edge products. The company has achieved notable milestones, including successful clinical trials and regulatory approvals, positioning itself as a key player in the competitive landscape of biotechnology. Revance's dedication to innovation and quality sets it apart, making it a trusted name in the field.
DitchCarbon Score
How does Revance Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Revance Therapeutics, Inc.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Revance Therapeutics, Inc.'s reported carbon emissions
Revance Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The company is classified as a current subsidiary, and any emissions data or climate commitments would be inherited from its parent organisation, Revance Therapeutics, Inc. However, there are no specific emissions figures or reduction initiatives documented. As a current subsidiary, Revance Therapeutics, Inc. may align its climate strategies with broader industry standards, but specific commitments or targets have not been disclosed. The absence of detailed emissions data and reduction initiatives suggests that the company may still be in the early stages of developing its climate action framework. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction, often setting Science-Based Targets Initiative (SBTi) goals. However, without specific data or commitments from Revance Therapeutics, it is unclear how they are positioning themselves within this evolving landscape.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Revance Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
